Paris, novembre 18th, 2021
This transaction was arranged by Caisse d’Epargne Grand-Est Europe, advised by De Gaulle Fleurance & Associés.
Through this financing, BIOSYNEX plans to secure the Group’s general needs and pursue its external acquisitions with the ambition of becoming the European leader in the field of rapid POC (“Point Of Care”) diagnostics.
These acquisitions are intended to build up a portfolio of synergistic and complementary technologies in molecular biology and in point-of-care. In addition, the Group intends to accelerate its international development through the consolidation of its distributors and the creation of new subsidiaries.
De Gaulle Fleurance & Associés (May Jarjour, Partner, and Vahan Guevorkian, Lawyer) advised La Caisse d’Epargne Grand-Est Europe (Mireille Maury) on this transaction.
De Gaulle Fleurance & Associés advises lenders on the financing of a portfolio of solar power plants developed by Photosol
Renewable energies Paris, December 14th, 2021 Photosol has secured a €42.5 million f...
De Gaulle Fleurance & Associés advises Lysogene for its funding by the BPI
Biotech Paris, December 2nd ,2021 The biopharmaceutical company, Lysogene, has obtai...
